



**Regulated information
For immediate release**

ThromboGenics Successfully Completes Private Placement Raising €56 million

Leuven, Belgium – 3 December 2010 – 14.00 CET – ThromboGenics NV (NYSE Euronext Brussels: THR), a biopharmaceutical company focused on the discovery and development of innovative treatments for eye disease, cardiovascular disease and cancer, announces today that it has raised €56 million through a private placement of 2,944,523 new shares.

The private placement, which was announced on Thursday 2 December 2010, has allowed ThromboGenics to place 2,944,523 new shares (9.99% of the outstanding shares) with a range of domestic and international investors and qualified institutional buyers in the United States at a price of €19,00 per share, a 3% discount on the previous closing price. The new shares are expected to be admitted to listing on NYSE Euronext Brussels following their issuance expected to take place on 8 December 2010.

The new funds will be used by ThromboGenics:

- to prepare for the introduction and commercialization of microplasmin, which has the potential to transform the treatment of retinal disease, in the US and Europe;
- to further execute its corporate strategy; and
- for general corporate purposes.

KBC Securities acted as Global Coordinator. KBC Securities, Jefferies International Limited and Petercam acted as Joint Bookrunners for the placing.

Commenting on today's announcement, Patrik De Haes, CEO of ThromboGenics said, "We are delighted to have raised this additional funding from a broad range of investors, including existing shareholders. We intend to use our newly enhanced financial position to invest in the highly focused team needed to commercialize our lead product, microplasmin, which has recently completed a very successful Phase III program in patients with vitreomacular adhesion. The success of microplasmin, which we believe has the potential to transform the treatment of retinal disease, is key to our plans of becoming a profitable, integrated company focused on cutting edge ophthalmic medicines, a strategy that is designed to significantly grow shareholder value over the next few years."

-End-

THIS PRESS RELEASE MAY NOT BE PUBLISHED, DISTRIBUTED OR TRANSMITTED IN OR INTO THE UNITED STATES, AUSTRALIA, CANADA OR JAPAN.

For further information please contact:

ThromboGenics

Chris Buyse, CFO

Tel: + 32 16 75 13 10
.buyse@thrombogenics.com

Citigate Dewe Rogerson

David Dible/ Nina Enegren/Mark Swallow

Tel: +44 (0) 207 638 95 71
.enegren@citigatedr.co.uk

About ThromboGenics

ThromboGenics is a biopharmaceutical company focused on the discovery and development of innovative medicines for the treatment of eye disease, vascular disease and cancer. The Company's lead product microplasmin has completed two Phase III clinical trials for the non-surgical treatment of retinal disorders. Microplasmin is also being evaluated in Phase II clinical development for additional vitreoretinal conditions. In addition, ThromboGenics is developing novel antibody therapeutics in collaboration with BioInvent International; these include TB-402 (anti-Factor VIII), a long acting anti-coagulant in Phase II, and TB-403 (anti-PIGF) in Phase Ib/II for cancer in partnership with Roche.

ThromboGenics is headquartered in Leuven, Belgium. The Company is listed on NYSE Euronext Brussels under the symbol THR. More information is available at .thrombogenics.com.

Cautionary note regarding forward-looking statements

This release may contain forward-looking statements, including, without limitation, statements containing the words "believes," "anticipates," "expects," "intends," "plans," "seeks," "estimates," "may," "will," "could," and "continues," as well as similar expressions. Such forward-looking statements may involve known and unknown risks, uncertainties and other factors which might cause the actual results, financial condition, performance or achievements of ThromboGenics, or industry results, to be materially different from any historic or future results, financial conditions, performance or achievements expressed or implied by such forward-looking statements. Given these uncertainties, the reader is advised not to place any undue reliance on such forward-looking statements. These forward-looking statements speak only as of the date of publication of this press release. ThromboGenics expressly disclaims any obligation to update any such forward-looking statements in this press release to reflect any change in its expectations with regard thereto or any change in events, conditions or circumstances on which any such statement is based, unless required by law or regulation.

THIS PRESS RELEASE MAY NOT BE PUBLISHED, DISTRIBUTED OR TRANSMITTED IN OR INTO THE UNITED STATES, AUSTRALIA, CANADA OR JAPAN.

Important notices regarding the offering

This press release does not constitute an offer to sell or the solicitation of an offer to buy any securities, nor shall there be any sale of securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. This press release is not an offer of securities for sale into the United States, Canada, Australia or Japan.

The new shares have not been and will not be registered under the US Securities Act of 1933, as amended (the "US Securities Act") and may not be offered or sold in the United States absent registration or an exemption from registration. The Company does not intend to register any portion of the placing in the United States or to conduct a public offering of securities in the United States.

This communication is being distributed only to, and is directed only at (a) persons outside the United Kingdom, (b) persons who have professional experience in matters relating to investments falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005, as amended (the "Order"), and (c) high net worth entities, and other persons to whom it may otherwise lawfully be communicated, falling within Article 49(2) of the Order (all such persons together being referred to as "relevant persons"). The securities referred to herein are only available to, and any invitation, offer or agreement to subscribe, purchase or otherwise acquire such securities will be engaged in only with relevant persons. Any person who is not a relevant person should not act or rely on this communication or any of its contents.

In relation to each member state of the European Economic Area which has implemented the Prospectus Directive (as defined below) (each, a "Relevant Member State"), with effect from and including the date on which the Prospectus Directive is implemented in that Relevant Member State (the "Relevant Implementation Date"), an offer to the public of any shares (the "Shares") which are the subject of the placing may not be made in that Relevant Member State, except that, with effect from and including the Relevant Implementation Date, an offer of Shares to the public may be made in that relevant Member State at any time:

- (i) to qualified investors (as defined in the Prospectus Directive or implementing legislation in the Relevant Member State) ("Qualified Investors");
- (ii) to fewer than 100 natural or legal persons (other than Qualified Investors); or
- (iii) in any other circumstances which do not require the publication by the Company of a prospectus pursuant to Article 3 of the Prospectus Directive.

For the purposes of this provision and when used elsewhere in this announcement, the expression an "offer of Shares to the public", or any similar expression, in relation to any Shares in any Relevant Member State means the communication in any form and by any means of sufficient information on the terms of the placing and the Shares to be offered so as to enable an investor to decide to purchase or subscribe for the Shares, as the same may be varied in that Member State by any measure implementing the Prospectus Directive in that Member State and the expression "Prospectus Directive" when used in this announcement means Directive 2003/71/EC and includes any relevant implementing measure in each Relevant Member State.